Building Adaptive Technical Operations for the Future of Biomanufacturing | BMWS25 Panel

How can biopharma organizations build agile, future-ready technical operations? In this BMWS 2025 panel, leaders from Project Farma, AnaptysBio, and Gilead share strategies for fostering adaptability, strengthening partnerships, and balancing quality with speed to market.

The panel features:
Adam Pfeiffer, Senior Vice President, Project Farma
Angela Goodenough, Executive Director of CMC, Analytical Development & Quality Control and Interim Head of Clinical Supply Chain, AnaptysBio
Jeff Davis, VP Clinical Manufacturing, Gilead
George Skillin, VP, Client Engagement, Project Farma

Together, they explore how organizations can design adaptive, resilient technical operations that thrive in an environment defined by rapid scientific advancement, regulatory complexity, and rising demand for agility.

Key insights include:
Establishing agile technical operations in a constantly evolving biomanufacturing landscape
Building trusted internal and external partnerships to strengthen execution
Maximizing innovation, flexibility, and manufacturing efficiency
Balancing uncompromising quality with increasing pressure for speed to market

About BMWS:
The Biomanufacturing World Summit brings together senior manufacturing, technical operations, quality, and bioprocessing leaders to share insights, explore innovation, and advance the future of global biopharma production.

Learn more at https://www.executiveplatforms.com/bmws/